ARCHIVES

FDA Proposes “Clarification” Of Clinical Studies regulations, Including Sanctions, Inspections

This article is from The Cancer Letter archive.

Vol. 04 No. 33 | August 18, 1978

Download PDF Visit The Full Archive

Related Articles

European Treatment Regimen Less Toxic Than American Method

April 26, 2013

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

May 22, 1981

NIH On R29 Phase-Out; Grant Review Appeals Process Changed

January 23, 1998

Biomarker May Predict Prostate Cancer Metastases

December 27, 2013

CCOP Q&A, List Of Research Bases

September 10, 1982

NCAB Approves Grants For Action Plan On Breast Cancer

September 22, 1995